Counseling + Methadone — Competitive Intelligence Brief

Counseling + Methadone (Counseling + Methadone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid agonist (with behavioral intervention). Area: Addiction Medicine / Substance Use Disorder.

phase 3 Opioid agonist (with behavioral intervention) Mu opioid receptor Addiction Medicine / Substance Use Disorder Small molecule

Target snapshot

Counseling + Methadone (Counseling + Methadone) — Friends Research Institute, Inc.. Methadone is a synthetic opioid agonist that binds to mu opioid receptors in the central nervous system, while counseling provides behavioral and psychosocial support to address substance use disorder.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Counseling + Methadone TARGET	Counseling + Methadone	Friends Research Institute, Inc.	phase 3	Opioid agonist (with behavioral intervention)	Mu opioid receptor
NALBUPHINE HYDROCHLORIDE	NALBUPHINE HYDROCHLORIDE		marketed		kappa opioid receptors, mu opioid receptors	1979-01-01
Bupivacaine-fentanyl elective group	Bupivacaine-fentanyl elective group	Conrad Arnfinn Bjørshol	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl)
Hyperbaric bupivacaine+Morphine	Hyperbaric bupivacaine+Morphine	Fundación Pública Andaluza Progreso y Salud	marketed	Local anesthetic + opioid combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptors (morphine)
Codeine + Diclofenac	Codeine + Diclofenac	University of Sao Paulo	marketed	Opioid + NSAID combination analgesic	Mu opioid receptor (codeine); COX-1 and COX-2 (diclofenac)
midazolam,fentanyl,etomidate,Cisatracurium besylate	midazolam,fentanyl,etomidate,Cisatracurium besylate	First Affiliated Hospital Xi'an Jiaotong University	marketed	Anesthetic combination (benzodiazepine, opioid, hypnotic, neuromuscular blocker)	GABA-A receptor (midazolam, etomidate), mu opioid receptor (fentanyl), nicotinic acetylcholine receptor at neuromuscular junction (cisatracurium)
Bupivacaine + nalbuphine	Bupivacaine + nalbuphine	Alzahraa Ahmed Abbas	marketed	Local anesthetic + mixed opioid agonist-antagonist	Voltage-gated sodium channels (bupivacaine); kappa and mu opioid receptors (nalbuphine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid agonist (with behavioral intervention) class)

1. Friends Research Institute, Inc. · 1 drug in this class